XML 63 R57.htm IDEA: XBRL DOCUMENT v3.24.3
Balance Sheet Components - Schedule of Accrued and Other Current Liabilities (Detail) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Accrued Liabilities, Current [Abstract]    
Preclinical and clinical trial accruals $ 6,689 $ 27,663
API and bulk drug product price true-up 12,592 50,978
Litigation settlement 28,500 28,500
Payroll and related accruals 6,144 20,267
Accrued restructuring charge 14,173 3,697
Inventory cost related 8,521  
Accrued co-promotion expenses - current 53,714 10,309
Roxadustat profit share to AstraZeneca   7,084
Lease termination related 4,558  
Value added taxes and other taxes 7,121 6,615
Professional services 4,396 7,103
Current portion of liability related to sale of future revenues 332 5,654
Other 4,401 5,021
Total accrued and other current liabilities $ 151,141 $ 172,891